-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KJdYzldyVCpVktoifNdG939nWOyJFHykvGVepqkJycFqGDrFr0V5JvxxSJ2yVUnt
 Tr0owxXxPSItUlBp3GOfsQ==

<SEC-DOCUMENT>0001144204-10-064206.txt : 20101201
<SEC-HEADER>0001144204-10-064206.hdr.sgml : 20101201
<ACCEPTANCE-DATETIME>20101201091827
ACCESSION NUMBER:		0001144204-10-064206
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20101130
FILED AS OF DATE:		20101201
DATE AS OF CHANGE:		20101201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		101223617

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v204321_6k.htm
<TEXT>
<html>
  <head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizer 4.0.6.4-->
    <!--Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved-->
    </head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of November, 2010</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number: <font style="DISPLAY: inline; FONT-WEIGHT: bold">000-51310</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">XTL Biopharmaceuticals
Ltd.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">85
Medinat Hayehudim St., Herzliya</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pituach,
PO Box 4033,</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Herzliya 46140,
Israel</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
20-F&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160; X&#160;
&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
40-F&#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;&#160;&#160;<font style="TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160; X&#160;&#160;
</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;N/A</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated November 30,
2010 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055)
filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and the
registration statements on Form S-8 (File No. 333-148085, File No. 333-148754
and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the
Securities and Exchange Commission on December 14, 2007, January 18, 2008, and
October 28, 2008, respectively.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals Announces</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Submission
of Draft Shelf Prospectus</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attached&#160;hereto
is an English translation (from Hebrew) of an announcement that XTL
Biopharmaceuticals Ltd. has filed a draft shelf prospectus with the Israel
Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE).</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">XTL Biopharmaceuticals,
Ltd.</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(the
&#8220;Company&#8221;)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">November
30, 2010</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div>
      <div align="justify">
        <div align="left">
          <table cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: times new roman">The
      Tel Aviv Stock Exchange Ltd.</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Via Magna</font></font></div>
                </td>
                <td align="left" valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: times new roman">The
      Securities Authority</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Via
Magna</font></font></div>
                </td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear
Sirs,</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re:&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Immediate
Report</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Re: <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">XTL
Biopharmaceuticals Ltd. (&#8220;the Company&#8221;) &#8211;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Submission of Draft Shelf
Prospectus to the Israel Securities Authority</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
November 30, 2010, the Company filed with the Israel Securities Authority (ISA)
and Tel Aviv Stock Exchange (TASE) a draft shelf prospectus on the basis of its
financial statements for the period ending September 30, 2010. According to the
shelf prospectus, the Company will be allowed to offer shares, a number of
series of bonds, a number of series of options to bonds, and
options.&#160;&#160;The scope and conditions will be set forth in the shelf
registration reports that the Company shall publish in the future, subject to
their publication.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The draft
shelf prospectus submitted does not include an immediate fund raising at this
stage.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Respectfully,</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
Biopharmaceuticals, Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
Relations, XTL Biopharmaceuticals Ltd.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel: +972
9 955 7080, Email: ir@xtlbio.com</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cautionary
Statement</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <div align="left">
          <table border="0" cellpadding="0" cellspacing="0" width="100%">
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="top" width="38%"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2">XTL
      BIOPHARMACEUTICALS LTD.</font></font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td colspan="2" valign="top" width="38%"><font size="2">&#160;</font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:
      November 30, 2010</font></div>
                </td>
                <td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:
      </font></div>
                </td>
                <td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font size="2">/s/ David Grossman</font></td>
                <td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td align="left" nowrap valign="bottom" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">David
      Grossman</font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="35%"><font size="2">Chief Executive Officer</font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
              <tr>
                <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                <td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
              </tr>
          </table>
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P"O`P$1``(1`0,1`?_$`,D``0`"`@,!`0$`````
M```````)"@@+`0('!@0%`0$``P`#`0$!````````````!@<(`04)`@0*$```
M!@$#`@(#"0X%!0`````!`@,$!08'`!$($@DA$S$4"D$B%1:W6'@Y&E%AD;$R
M0B-TM=6V-W>7TR26%Q@S4Y76&1$``0($!`(%!0D-!P,%`````0(#`!$$!2$2
M!@<Q05%A(A,(<3)"%!>!D5*R(W-T-3:QP=%B<I+B,U.3LQ4)H8*BTM-4%O!#
M520T)948_]H`#`,!``(1`Q$`/P"_QI".ISD3*8ZABD(0IC'.<0*4I2@)C&,8
M=@*4I0W$1\`#3C@.,.&)X12%YI>U2Y>IW(BYT+B-AO%4SB#&UOE:F>Y92/9G
M\YDUW79!2,F92*9P,C%-JO7'#]HJ1B8WK3I5(`6/T]0)ET3IW92CJK2BJOS[
MJ:]U`4$MY9-@B8!)!S*EYW``X<IFE+_NPJAN:J2W-)53H5(D@DJ_Q)E/B)3P
MECC(6:NV!W"J5W*N+,#R!K-<7H]E93<G1LGX_</B2@T^_P`"FU6D63"4*F@,
MI!23%\W>L'!DTE#MG!0.0JA3!JH-8Z6J=(7I=J?6'6I!;;@!&=!F`9<B""%#
M'$<8LW3=_IM1VQ%PI\%'!29SDJ0/O$$$3D>D`Q(EJ*QWT-(0TA#2$-(0TA#2
M$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA$/_>EM7._$G$V1Y!\#<C%K%NPDX>VO
M*=)6HU=NWQVQ5ZH!;!*1:,VS=N&<S0@2"2Z&X?YEB#D#`)DR`,VT#3Z;N%]3
M:=2H)IZD!+:PM2,CDY@8?#\W$X&77**ZO=O%+:E7"SK(>8FI20$]I,N)F#YO
M'#E,SPQIKX@]I0[E-:RCCZP9BRA6LG8BC[5#+Y+H;;&-)@G=KH2SDB%GC8V;
MBXY)]&2:D,LJHT72-N5P0@B`EW`;^K=FM*+HW4V]+K=<4'NUEQ2@%^B2"9$3
MXCHBE;?NE?/7FT5Y"J;.`L'*,)R(P2"#Q''`X\H^DY'>SX\QK;D]?*7!VOUC
MDEQ7ST]'*N&;]'Y#I58DH2FY%6&TQL)>8VUS$.JW=P"<J*!G;+UQ)9-(!,5-
M;K1+S9]UM/4U#ZCJ52J*]4B>[>04+6%K1V2I!0E4IRG)4I<B1C'U?-M[K65P
MKK$`_;:B2DJ"D`I20)3"E)Q`P($^$Y@F0]BS3R1SCV!./N+>`G';*5.5YA7B
MSO\`DMS`O,7`,+C6*+\;(9C!X_PW6&]D:^2Z6^`HI%X\?J-TECI(I'3*4CK8
MO6T5EMVZMUJ-3W-IUO3[:13TJ,V5:\I*EN*(E(3)``F)D@F:8[*XW5[;BULV
M*WJ2JZN'O'E#@GLA*0)@S,A-6`Q(E@8RO[+_`'!N\)W).6$=5[1GZ+:\=L2$
MC[MGV?C\08_8*/HA1=1.OXXB94D3U,Y^]/4#E\Q/=9M'MW"X!N4N\>W!T?H7
M1UE+S+3BKM430RDNK,CA-PB>(0.7`D@1W.AM2ZHU1</EEY:!J2EF2<<?-\P<
M>&!Z3RD<1^X/WV^YS@KG-RTPSC+.M<@\=XPSQD"E4J&<8JHLHO%UN"F%6<8Q
M6DG\:J]?*-T"``JJF$YQ\1U(--;6:1NNGJ*XU;3OK3U*VM<G%`%2D`DR!D)D
MQT&H]Q;_`&V]U-%3+'<-O+2,$\$K4D<4D\`.?'&,/?M&/=R^<35O[-X[_=6N
M\]CFB?V3_P"]7^&.D]J>IOACWD_Y(Y^T8]W+YQ-6_LWCO]TZX]CNB/V3W[U?
MX8X]JFIOACWD?Y(X^T9=W+YQ-6_LWCO]U:Y]CFB?V+_[U?X8Y]J>IOACWD_Y
M(Y^T8]W+YQ-6_LWCO]TZ>QW1/[)[]ZO\,<>U34WPQ[R/\D6MO9T^??*?GOB?
MDU:.4E^C;[-8\RA2ZY47,;4H"IDC8B6I9I9^V40@6K5)X99^'6!U`$Q?0`[:
MI3=32MGTI7TE+9T*0VZTI2LRBHDA4AQX2BX=O-05^HK:[5UZIN)6`.'2KH`Z
M!%C;5618,<#Z-<*GE,N,H"*\7;TYW\G\[\U)?$63[ZPG:&QA<GN4HAM5("*4
M]8KDDBVB%!?L&J3S_+I&$!#K$#_G;^G6O-W-H]$:2VR9U)8V'D793M,"I3JU
M"3J"5=DF6)'0)<H\X?#AXB=T=Q-\JO1&J:QEVP,LUJ@A+#2#-E82CMI2%83Y
MDSYSXQ8>UD2/1Z&D(\&Y1W*T8\XYYLO5)=BPMU3QK;)ZMO2L4Y,6TS&Q+ARP
M6".6352>B1PF'Z,Q3`;T;:DFCJ"BNNK;;;+BG-;ZBM9;<&;+V%K"5=KE@>/*
M(-N9>;KIW;R]7VQ?7-';*AUCL9_E4-J4CL>EB!ASB,'M)\L^2O)2>S0SSY8G
M$ZVJT'17E:35I["K^KKS#VP(RBA5&<>Q]<!1)DC[TPFZ-MP#QU>7B"V^T3H:
MFMBM))"':AU\._+]]@@-Y`05$IQ*L<!TQE;P@;Q[H[I5]]I]QE9FJ)JF53_^
MG2S^L4^'#-*$A6"48&9'$83B;?6:8W%#2$-(0TA'YW;1J_:N6+YN@\9/6ZS1
MXT<I$7;.FKA,R+ALX15*9-9!=(XE.4P"!BB(#X:Y2HI4%),E`S!Z"(X4`H%*
MA-)$B(U>G?![;COMW<OI=O3HEPCQRSJO,Y"P>](B<8^N^8\*M;\6&<;"D1Q2
M9)\4S-,1ZC1+EN.WO3;;-VVU<-56$&I7.[TTD/#":O@N2Z%@8GX0(C+.XFE5
M6&Z&IITRM[QFF0P'#`]8.'DRGB3$JW8\[VM+XG\(N1V#^1,V#YQQKJ$UE'C/
M&/W@E?WN*G'Y6JF%8@RRO6K(QE\EFZ[1,@[DC)!8P`";0XA"-Q]N:J]ZBI;E
M:4')5K2W4$">0C_NJZL@(/6D3,U1,-":\8HK&_27%:>_IT%38499YX903TJ(
M/*4U823%8JX6G.7-;DI,6F2;262>07)7*7F(1,:15PZF[G=)1-I#UZ)1#K,W
MAXA)1%HW*&R;5BV`1V*01U<=,Q;M-V5+*2EJVTC'$F0"4"9))YG$GI)ZXJBI
M>K=47PK[2WGG,,)F1/1UDX#E,#@(VC/:UX!5#MS\2*-@V(*PD\@/TB7+-EU:
MH$*M<\I3+1N$XZ*XV\XT'`IHIQL6D(B"3)L0=NLZ@FQAK/4]3JR^.W)TJ%,#
ME90?0;!,AY3YRNL]$HU;IBP4^G;2W0-`=[*:R.:R!/KD.`GY>),?GR+V@^VC
MEN^W'*.2>'>([AD#(%ADK7<[5,,IE64L-BEUQ<R<L_.E,I)&=/5S"<XE(4HB
M/HUQ2ZWU914S='2U]0W3-("4)!$@D<!PY<I\H^GM+V"H>74/4S:G5J*E$YL2
M3,F4Y"9))E+$DQ#)WPNUQV^N-G;4SYF#!7%3%V,\FUAUCHM?N=;92B,S$A*Y
M#K<3(E:+.I1TF4KR->JHG`2"`D./N@`A8.V^K]3W75]-17"M?=I%)<S(4009
M(41RZ0#.(=KC35BI--OOT],A#R2B1!5\(#IQBF_VYL?4G+//;A]C')-:CKCC
M^_\`(+'54N=4ERJ'B[#79B7*WDHE^1%1)4S5VB/2<"F*(A[NM"ZMKJNW:8N%
M90N%JJ12.95"4QV>(GSZ^44/H^FIZS4E+3U2`MA3J04F8G-:1RD><;(G_P"(
M/:<^8OA+_P`=._OW60/:!K3_`,E4_G#\$:E_XCIO_:-?XOPQ1_\`:'N,V!>*
M'/2`QAQSQ?6<1T!S@.CV=Q5JFBY;Q:U@D9^V,WLJ=-TY=J"[<MF")#FZMA!,
M/#?<1TCM/>+G>]-*J[J\M^I%2M(4J4\H"9#`#A,Q06Y]KH+7>$MT#8;06TD@
M$GIZ29>081.K[(?_`"'YG_ULQU\G)]5GOQ]<4'T=?QHL+9WZC?\`G?OJBW]J
MB8MZ.!]'X/QZX/`^2.1%1+M7R\77NX1>;!.R#.(@X.GYUEIF7D7"32.BHQE*
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MF\>9!DS"G$5'(;1G%JSZX`)A:UV:8OI"$E7IBE$2MO.3='`/>ICJ$:YV-UYH
M2D5=:YENJLB/.?IU%00.EQ"DI6D3P*I%(YJBT-IO%?M/NW7ILEL?>M^HE^93
M5@0VIT_!:6E:VW%=",R5GDDQG+DF[P.-:!<<@VA-RM6J77)>S3R;-KZ\\-$P
MS)9\^!HR$2@[<B@B;I3$2]0^&X:JRUVZJO%TIK309#6U+Z&F\R@D9UJ"4S4>
M&)&/*+^U%?+?IFPUFH;L5BUT5,X^Z4I*U=VVDJ7)(Q4<H.'.,9N*'-K`_+IS
M<D<+-;,B:D-H!>P'L57"MATV(\F2+2:B"[CUL^\4MUAX`0-ONZF>O-M-7;>>
MK'4R&$BK4X&\CH<GW>7/.0P\],NG'HBKMHM]=O=Y7:]G0QJ2NW!HO=ZSW0DZ
M7`C*0HYL6US'+#ICWW,&:\6X$ICZ_P"6[I#4FKLC`CZ]++B"KYZ<ICHQL2P1
M*J^EI1P!1\MNW345-MOML`B$:T]IJ_:MN:;-IRF<JKDO'(G@!S4M1DE"1/%2
MB`,,8L'6&M=+:`LCFHM85K-#:&\"MPXJ5B0A"1-;BS(R0A*E''#`Q$):^_'Q
MUB991G6,597M48FH)"S#D:S6BN2E-L*S:/?RCE]Y1B^)?-*B<?0)2^YH6@\*
MFMZAA+E;6VZG>(Q1F=<(ZB4MA,_(2.LQC"[_`-0?:VDJU,6BU7FMIDF7>966
M@>M*2XI4NC,$GI`C+;C-W1.+?)J<8TR'G9;'F0)18&\33<C-6L.ZG7!@$2MZ
M_,-'K^"EG:FP]+<K@CHWN)#JO];[&Z^T-2KN=6PW5V5$RI^G45AL#FX@I2XA
M/XQ24CFJ+DVI\5NTF[-8BS6NI=H-1.$!%-6)2VIQ1]%IQ*UM.*PP3F"SR08D
M8U3T:4AI"(W^ZIP*IO<.X?9`PK-#&1-[B&RUZPS=Y!-(H4O)=>9.E8ATX=FZ
M54:_.H'5CI4@&`IV3DQ]NM-,2RO1>IJC2M^:N368TZB$.H'IMJ(F)?"&"D]8
MEP)B.ZIL=/J"S.T+T@YE*D*/HJ`PQY`\#U8\A&I^DHUU%2<C$21&Q9*$E)")
M?%:.F\@T3D8IVXCGOJ4@U.HU?-@<('!)=(QDUD]C%$2F#6XVG$NMI=1/*I((
MF)&1QQ!Q'D,8\J&E4KZV)SD98<QQ$Y$CHPF<8N/^RI<',77&2R;SMN,O6;7?
M<;V%YB3%]&(LF]E<:OG\0W>V+(<^P4*`Q\O98E\#&$.`&`&8/%`'K.'EY]WN
MU+6,!G3#"5HI7D=ZXO$!R1D$)/0DC,KKR^[>>T=@I2TY?'5(74`Y4I&)1,3*
MCUXY1T'-U2O!:SF!(2B\H:0B#SVC+ZHODS^MXK^52H:LC:?[<4OY#O\`#5$+
MW`^RM1Y4?'$4%^U']9CP/^E'BC]O$UI[7/V/N7T-SXIC.6A_M31_/(_B(C;5
MZPS&P8UT'M4?UF%:^C+CO^*+QK6&R?V27]+7\5,9OW>^NT?-I^X8EA]D/_D/
MS/\`ZV8Z^3D^H+OQ]<4'T=?QHF6SOU&_\[]]46_M43%O1P/H_!^/7!X'R1R(
MH3XYQO;<T<GC87ITJ[AWV5\F6"FRKQJHL1).M.;&\DK`M))(G3]>C6$=&G<G
M;G'RU3HD*/N"'K#>K];],;?)U'<FD/,V^B;>0D@$EWNTI;"2>"BI02%<4A2B
M(_GCTII6^:[WF=T-8ZA=,[=[H]3NK2H@=P7E+>S`><E*$%>0X**`#RBW3C;M
MI\+<<5)E5B8+IER72:IHR=FOT6A:;+-N0(!5WSR0DBJ@U.N?<P)-2H()[[$(
M`!KSQO6]&Y=[N*KBNZU5-,S2TPLM--CDE*42G+A-14H\R8]G],>&+8_3%E;L
MS6G[?69$`+>JFDOO.&6*E+<!EF,SE0$H'HI$A$(7=?X"TGC(%/S]@-F]I]-F
M;.C`V&LL9!V9M3;<=)>6K<[4W2RQY",:/PCUBBB"AB-G")#)"4I^@NH_#[N]
M=M;JJ-&ZR4BKN33!<:=4!-UB80ZTZF652AG2<TIJ!,YD3.!_&+X=['M5ZENC
MMLA5!:G*M+3["%*DQ4$%QEU@DYD(5D4"G,<BTI*)!4DR7XLY%2O)GM2Y-O5G
M=^O7:&PSE&C7=V;;SG]BJU=?M#2[@``.E>:C3MW2GW5%3#][5!:HT?3Z'WZH
MK-0HR6ER[4;].GB$M.O)4$3Y]VK,@'H`C6.D=RZG=7PCW34ER5FO;=@KZ:I)
M.*WF:=:2X>MU&1P]:C&%W8%W]<Y,;;>##$8[CZ`V6O0B8?O%#QU:WB[\VP_E
MU?W&(H+^G%^MU?/A_P#'_=K(Q"Y%W7(O<QY],<1UF96;T:/N<I1*`C[]>(J]
M.K:S@+AD%=@0XHN)220CEW9SB/4<GD-P,!"AJQ='6ZR[';/*U+7MH5>'J9%0
M^>"W7G0.XILQE)""H)E(2.=<B3**<W,O6IO%5XCD:!ME4M&EF*URGIQCW;-.
MS/UBI*1YRUAM3DSQ[")A(!%C/%/;PX?XGI[.IQF$:19SD9I(2MDO4%'VNRS[
M@J?2N]DI*80<F3,X.(F\I`$D$]]B$*`!K&U]W@W%U#<%7&HNE6Q,S2VPXIII
ML<@E"".'2J:CS,>F6D_#?LOH^T(M%%8+?4Y4!*WJII%0\Z>96MP*..)RIRH$
M^RD"(9.ZQVYJ-A"KM.2O':'/3:]$S4:UR!2XEPY3C:\L^=D2@[K4Q%0SB'*C
M+&31<MTS@FF=5-5$";'`=+;`;T7/45P.A]9+%76.-J53/N`*4YE!*V'@1E<F
MF:DE0)("D*F"(P]XO_#/8]#VI&[6V#/\O:IGT"KIVE*2AO,H!JHIP,6Y.94K
M2DA*2I"T`=J,U.+',*[YT[9F?[A)V%VCF?!N',P5^0M390A)5Q*UW&<S-TFZ
MF5+XDF%6I$CJJ"'Z1VV.IZ3#JK]=;<VW2N^=JM++*3IBZ7&C<0T1-`0[4H0^
MS+X`.8!/)"DIY1>^U&^=[W!\+.H=4/OJ3KFPV2XH<?$@I3S%"Z]35'4L@)*C
M+%Q"E<Y":#6;XVW%8/VDKN?_`/%_!B?#O#MC%KGKD77W9;I)1#WRY3&F$')E
MHZ9>"LW$%HZP9%4*I&,!ZBJI,BNUR@!@1/JZ-GM&"[W7_D5S;"[31K&1!P#C
MPQ'64HXF6&;*.F*PW+U2+/:S;*50%?4)D?Q4'`^ZK'^[/I$4-,5\=\P9EJ.9
MKGBVBR=IJG'?'J>3<M2,:F`H5&DC*M85)\<GY3IQYJQUP;)=2PLV;E?;H0.(
M::K+I;K<_3TM>ZEI^J<[MH$'M+E.75AA/A,I'%0C/-OLURO#=154J%+2R@K6
MJ8Z1,DDCIG[AZ#+/OLX=QR5[</+NMWZ:D'JF`<G?!U!Y`P;?=PC\473S>(OS
M1GOTJS./))SZZ0Q-E%6!W2`#LKMJ)[AZ2&K+`NG92/YHSVV"<.UZ2/[X$NB<
MB>$27;_4BM/WI*'B11O'*L?<X\P<1[H](QM-X*<A[/"1%DKTDRF8"?C&$U"2
M\<NFZCY2)E&J3V.D6+E(3)N&CUHN11,Y1$#$,`AK%CC;C+BF7DE+J%$$'`@@
MR((Y$1JY"T.(#C9!0H`@C@0<08_JZ^(^H@\]HR^J+Y,_K>*_E4J&K(VG^W%+
M^0[_``U1"]P/LK4>5'QQ%!?M1_68\#_I1XH_;Q-:>US]C[E]#<^*8SEH?[4T
M?SR/XB(VU>L,QL&-=![5']9A6OHRX[_BB\:UALG]DE_2U_%3&;]WOKM'S:?N
M&)8?9#_Y#\S_`.MF.ODY/J"[\?7%!]'7\:)EL[]1O_._?5%O[5$Q;T<#Z/P?
MCUP>!\D<B*@/:TCFS_N6(J./+ZHP<W2+4%`*(^M%"0:%\OJ]"GDNS^(>.V^O
M0_?A]3.R*4@**7?4D&7`#LJQZII]^4>+WA'IFZCQ3O+<RS:5<EIGT_*)PZY*
M/N3BW_KSQCV@B*KO,)M%.#%U,Y*D95*[8V49"<0ZR.OC0W3$R/COY@M%%0';
M\P3??U>/AQ+J=VJ(M3RJIZ@+E\'NEG'JS!/N@1D?QP):5X>;D7`DJ36493.6
M"N_0)I_&RE0PQRD\IQ@%VZ2/0[6G-DZQMV1U,L^HEV`!*8N+XH'>X[`(@97;
M[NK5WP*#OMIF7ZP*H9^3UM4HS]X8.^__`")K7/\`J<EQR_\`U[<_O1\]V.%7
M2%:YC+L0,9\C1J*JS*00`YG2<;D8[<I1'P`PJ@&V_NZ[3Q5)0NNTTAR60U-0
M#Y)T\XZ7^GXI:;9KI3>#@IJ27ERUTO[8\3[)"31SS0L;J3!,9-+%%V<,A6Z1
M6*^7L$`G("EOX^9ZLJH!A#\T1]P=2KQ/=XC;6F0S^H]?9"N6`;<RX<Q,"(-X
M#D-.[Y7%ZJ_]VFUU)3,3.8O,A6/+LE7EBV^```;!X`&O/N/8R,*NXRW8N>#_
M`"53D>D&X8UD50$P;[.F[U@NPV]T!]?33V^X.K+V<4ZG="R*9!+GKR1[A"@K
M_#.?5%'>)5%.YL/JA-5+N?Y6LX_""DE'NYPF77$!W;+4=?\`#_N?(]9_4_\`
MCQ:E/+W'R_6QQ3DLIC[>CK\D`#?T[:UQOBE@[B:%6@#U@7=H$\Y>M4Q]Z/.C
MPJJJ?89NJDJ/J?\`QFJ,N6?U&OQETRBQ-S*Y88RX2<<,G<DLLO@1J^/(%5VS
MB45DDI2WVEX/JE7I<"14P>?,V:942;)``""13&6/LFF<P83L-DK-1W=FST(^
M6>5*>,DIXJ4J7`)$S_8,2(]=[M=*:S6]RXU1DTVF?E/)(ZR?>XG`1J;>27(/
M*_,+D'D7/^4G3JQY,S!;CR)XU@"SI*/3=KDCJG1*NTV,H6)K\?ZO',$2AN<"
M`80$YS".X[-:*#3EH:M='V:1A$LQXJ/%2U=:C,G\$9!O%TK-37A54YBXZOLC
MD!Y/(/>`&)Q.R9[-?;/KO!K@LQQCDJNQ<QEK/T8:Y\DDI!J1RB[?VF%%@AC-
MR"I0%>#I5:=?!IDC!T'='=*!_P!41UD3<#6%1J74RJZG6H4=,0A@@R,DF?>#
MH4I0G/C*71&H-(:;8L=A11.H'?.IFZ#CQ'FGR`XX#M%1YQ0A[MW`"7[=?,N^
MX;;-':V(K5YF1<#3CE-0Z4EC6?=K^77U7!TDR.)2B2H+1+H`#WQ4$E?R52B.
MH-"ZL3J^P-5Z\HKV@&WDCDM(\Z4S(+':ZR3UQGC7FG%:=O:DMS]6=.=!\IZ9
M#$<#U@GG%H7V8?N;&R707/;TS#/'7ON*(5U8>/4O)N3*.;/BIH?KFL?"LL<5
M',IC954%F1??&/"K=`;%9")J7WET6B@J4ZJMB1ZM4$"H2!+(Z20%SYAP8GH6
M9>E%L[6ZJ-QHOY+6JG5,CL'I1\'W.(ZI@>;C;RU1$6[$'GM&7U1?)G];Q7\J
ME0U9&T_VXI?R'?X:HA>X'V5J/*CXXB@OVH_K,>!_TH\4?MXFM/:Y^Q]R^AN?
M%,9RT/\`:FC^>1_$1&VKUAF-@QKH/:H_K,*U]&7'?\47C6L-D_LDOZ6OXJ8S
M?N]]=H^;3]PQXKV?^]-%]J^@9JI#_C[+YG4RY>:Y<4Y*-O4=420:<!6QKXQZ
MK=]#2AGIW)A\T%"B0"@/2(#Z==CKW;M>M*VGJTU08##2DRR9IS,Y^<(_#HC7
M;.E[>Y1N-!:EKG,J(Z>A*NF)AOM?E>^8M:O[SP'_`*EJ!^P=S_R(_=?IQ-/;
M%2?[=/YZ_P#3CJ?VOVN$*8X\%;4($*8X@&:*^`CT@)M@'XI#L([:X]@[I$OY
MBD8<VL/CQ]HW@I%+"33B1('GK_TXQYXD<GB80Y-X_P"2;B(<G@EYV0F+1!-C
M`Y?)U/(#=S\--&:@>41U(Q+65!5$!Z2KJMP+X`;PVAKG11UEMV]I-IP)JU4K
M7=+.">]:"5(S<9)44Y5<2D&>,H\8-JMSV]L-]4:YJ6UKM;5RJ4U"4XJ[AU;C
M;A3.4RD*S@&4RD#"<XN\8\S7B;*=2B[K0<B5*SUR59(O4)&/G(X_E$53*J*,
MBV%<CB,>H=6RS=<B:J1P$IB@(;:\QKOIJ_V&O7:[Q1OT]>A4BE2%"?6DRDI)
M]%29A0Q!CW?T]K32>J[0U?=.W&DJ[4\@*2XAU!$B)R4)S0H>DA0"DG`@&*]_
M>=YG4'(\95^,V*K"RN)H>TH6O)$Q7G"<G#MY2-;NF%=J+)^S,JWE)1-P_57=
M$0,H1!0J28CYG44NOO#1MI=[-4/Z[U'3JI4N4Q:I4N@H<*%*"G'E)5(H1).5
M.:14"5#LR)\WO'/O=IS4UOI-I='52:^M16AZL4R0MI*T)4AI@+3,+<S+*EA$
MP@A*2<TPG-S#^`9CCIVF,BTZT,BQ]RG\+Y3OMN9=(`NRE[;7Y!^A&NQ#Q%W%
M1`-FZH#^0HF8ON:J'5>KV-:[^4=UH59[6W=J-AE7PD,NH25#J4O,I/2"#&@-
M%;<UFV'A!N>G[HCN[R[8;A55"2.TAQ]AQ00K\9MO(A0Y%)'*<8:]@DI#N>3:
M:I`434C<3)J)B4#@HFHI>R'3,4?`Q3E,("'W!U:?BZ)`L*A.875G#C@&(H;^
MG&E*G-7I4`4D4`(/#$UG&,++*WM_;`[BHVAY"/'=,96J:FX<K8ADD[?AB^N'
M23U"*54**!Y2&;.3(F2$1!-\R`IA`IBF&SJ)5OWXV7-O:=2W="PAM<S^IK&`
M"DK'$)<*<P/[-9/$$125X1>/"5XG/YT^PZO3#E2XXV0,J:B@J20L(/FE;(44
ME/)UL3D)*BV1C'/&'LQ5"-O&.,B52S5R2:I.".F<RQ!PQ,<@&.SEF*BY'D3(
MMAW*J@X(FHF8!`0U@"^:8U!IJXKM-\I'Z>N;,BE2%"?04F4EI/%*DD@C$1[`
M:6UYH[6EF:OVF;C25=L=2"%(<1-)(GE<3/,VL>DA8"AS$0D=X;GACUUCA]Q<
MQ-:8VV6*V.V"V49NO/T9"%K5;B7:,DE6#R;)15H[G9J1;(BN@F<WJS=,P*;'
M.4NM/^'+:2\&]HU]J!A=/;Z=!]40X"EQYU8*>\""`0VA),E'!2B,N`G&$_&S
MX@].M:4=VETE4M5EZKEH]=6RL+0PTA06&5*3,*=<6E.9`/80#FQ4!'TG#3C-
M9\,]K7E'/V2"?-;YGC".9;<A`"Q<?#2%=_VIL492(Q5D*8._A&305.Z(@!>K
M9V0NW5N&OQ;E:XH=3;^6*DH5I-JM-RHF2[F!0IT5;:WU@SD`DR03.7R9/".Q
MV4VDN^A?"/JMZXLK3J/4%@N3X9RJ[U+9M[[=,V4RS9US+@2!/Y0#$SCW+NF=
MI\G=(2QC6[MR>R1A_&6,E9*:;XZHM6K,I&66ZR`"U2MUB?32I7+IU#Q(F:L4
M-O);@LLH7WZ@CJB=&:U5HU;S]/2-/U;P`SK4H%*1B4@#I.)/.0Z(W#J;32-2
MLHIGWE-TZ9DI`G,],YCEASY])C!+A_[,5QHXK\CL8<A9G.^2LVFQ3-FM<#CZ
MYU2H158>6QDW4"M34LK%>:[=$K,D<KY%OL":CI%(3[E*)326_P"\5[O5I>M;
M3#5/WR<JEH4HJRGS@)\,PP)Z"9=,1ZR[9VBSW%NX9U.J;,P")"?(G$\#(^4#
ME,&S2'HU4(X19,1A=T/M98:[HV+Z11<C6>?QM:\;VPUEI.3ZA&Q4G8XAG(M0
M8V>L*-)<`:/(&S-DD#+)&,`IN&J"Q/?$V&8:-UG<=&5KM51)2ZR\C*MM1(29
M&:58<%)QD>@D<XC>I=,4&IZ5-/68+09I5*9$^(XCJ/'B!Q$P8BL,^RU4/C]E
MG'>;<4<[\\5C(N+K7%7"IS*%!H!@1D(Q<#JLWB(+%*[BI=F91H\0-[Q9LL<@
M^G4YN>\M9=Z!VVUUOIU4KR"E0SKX'GPX@XCK$12V[945IK$5U'4K34(,P<OZ
M7_7`S!(-J]$JA4DBK'*JL5,A55"D\LJB@%`#G*GU&\LIS;B!=QV]&^J6BSXP
MVY_\-J_SZXL9$XM6B\SV.83(:U96>6VM1T=+3$=\6;+%V5$C9C*F*Q6!VO%E
M2/UB'20PB'B`:[_3&H'M,7EJ\,-H=<;"AE42`<R2GB.8G..JO5J:O5N7;WE%
M*%D8RGP(/5T=(B#_`(Q^R]X5XR\B<)<AX7EEE^U2V%,E5C)$?6I>DTEG%SSR
ML/0>HQ;]VR5%VU:.S!TG.GN<H>CQU8EZWCNEYM-1:ET;"$5#2D%04HD!6!(!
MPG*(1:-LK9:+BU<6G5*6TH*`*9<"",<W2!%HW5.19D0#]R_L'8M[E?(J/Y#W
M+D5DK%LK'XZ@,=DK-3JM5F8M1I`R4S(I21GDR<KL'+D\R8IB;=``0!#TCJS=
M(;FU^D+6JUT]*R\V72O,I2@>T`)2&$L)@]<074NA:'4M6*NI<4A02!("?#W1
M$?'V0K`/ST,X_P"@,??XFI5[=KM_L:?\]<1OV06C]NO\W]*'V0K`/ST,X_Z`
MQ]_B:>W:[?[&G_/7#V06C]NO\W]*.I_9!\`'(8@\T<Y`!BF*(_$#'WAU`(?]
MS[^GMVNW.@IY?EKCZ3M%:4J"N_7@?@_I1+)Q^[*N"\+*V%I9[Y9LOUFSXU7Q
MQ)UNT0<+$I)HJ*1*S:Q1LE$J"^C)^-7B2*-UDA*9,QA\=A$![#5/B.U9?J>C
M3;:9FW5E#4H>;<:6M15E0I&1:5]E2%!1S),P>B*3T3X+=O=*W:Z5MTJZB[6Z
M[4SS+M.\TVE*>^=2Z%MK2<Z'&RGL*200<9\HQANO81>!.NU,7\C!BZP[5.8L
M?<*BX>S#9`3?HVRTC`R\:UE`2(/2!U$$Q';Q#5AVSQ8H-(E-_LJ7:]'ILNA*
M2>D)<0LI//!1BEKY_3T6FM<.D-3N4]J6H_)OL*4I*3Z)6TZA*Y<)Y$S'$1E[
MQ-[/6$N/-JB,BWNPOLT7F"4;O(%*9BF<12Z]*HF\PDLRKB2CU22D6R@`9NH\
M74(B8.LJ8'`I@KO<+Q%ZJUI;W++;66[;:704N%"E+?=2?04Z<N5)&"@A(*N!
M,I@W1LWX+]`;7W=O4UY?<O>HF2%-%U"4,,K!F'$-365.`@95+60GB$@R(DZR
MWCQKEC%]_P`8O))S#,[]4IZI.I5DBDN[CD)Z/7CEGK=!?9%9=N1P)RE/[TQ@
MV'5&62YKL=YH[TRVEQVCJ6WDH42$J+:@H)41C(D8RQC5&K=/,ZMTO<=+U#BF
M6+C1/4ZG$@%2$O(4@J2#@2`J8!PC#C@[V^:KP?<9"7K.2;-?/]PF]60>DL,1
M$QI8X:L>9.@HT&-,85!=_#)P.!_`O0&WI'5B[I[M7/=+U$5U(Q2"B4Z1W:E*
M*^]R3!S<)9,)=)BEMA/#I8]A'+HY9[C55_\`-$L!8>0A`06"Z04Y)DYN],YG
MD(]UY.\3,,<M:4E3<N5X[TT<LJ[K5HB7'P;:JH_63!-1W"2I4U1(DN4I07;*
ME5:N`*'6F(E*)8QHK7FIMO[FJZ:;?[M;@"7&U#,TZD&<EHX&7HJ$E)QRJ$S.
M?;I;1Z)WAL`T_K.G+C3:BIEU!R/,+(EF;7(RGP4A04A8`S),@1"7/]@ZPH2[
MGXD\EVK>OKJ&`I+!1W83(-NH>A)TM"S[5B^.0@^)A3(41W]Z&M/TGBSIG*=/
M\WL>:L1P+;XR3YD!QM13CCQ)ZXPE<OZ>56S5$:9U2IJW*)FEZG5GE/`$MNA)
M,N)RI$^`$XRSXO=F+!^$;/#WS)UED,V6F`>-I*#BI&*:P5$C)%J/F(O5ZZDL
M^6G5V[C8Z17:YFY3%`12,(;A7NN_$IJW55`NT69ENV6]U)2XI"U+?6A6!3WA
M"<@(P.1(49GM`81<6TW@AV[V^NS6HM2/N7V\L*2MI+J`BF;6G$++699=4#(I
M[Q10"`<A(!B94"$`O0!2]&PEZ-@Z>D0V$O3Z-MO<UG"0EEY1M>.VN80TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
G-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
